DUET-102 / Scopus - LARVOL DELTA

Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD1 immune checkpoint blockade. (PubMed, Neuro Oncol) - "Our results suggest rationale for the GBM immunotherapy using CpG-STAT3dsASO to disrupt GAMs-dependent immune evasion, thereby restoring sensitivity to PD1-blockade and facilitating T-cell-mediated antitumor immune responses."

Checkpoint inhibition • Journal • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor • Transplantation • CD4 • CD8 • STAT3 • TLR9

Scopus BioPharma’s Subsidiary—Duet BioTherapeutics—Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire) - "Scopus BioPharma Inc...presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma...The featured data shows: Intracranially injected DUET-102 sensitizes malignant glioma to systemic PD-1 blockade, triggering complete rejection of both orthotopic GL261 and PD-1 refractory QPP8 tumors in the majority of treated mice...DUET-102 was well tolerated and demonstrated unique suitability for intracranial injection, with optimized activity and tolerability in the brain compared to single-stranded ASO designs."

Preclinical • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire) - "The featured data shows: Intracranially injected DUET-102 sensitizes malignant glioma to systemic PD-1 blockade, triggering complete rejection of both orthotopic GL261 and PD-1 refractory QPP8 tumors in the majority of treated mice; DUET-102, as a monotherapy, inhibited tumor growth and extended survival of mice in U251, GL261, and QPP8 models of glioma; DUET-102 was well tolerated and demonstrated unique suitability for intracranial injection, with optimized activity and tolerability in the brain compared to single-stranded ASO designs."

Preclinical • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire) - "Scopus BioPharma Inc...today announced that Marcin Kortylewski, Ph.D., Co-Founder and Senior Scientific Advisor of Duet and Professor of Immuno-Oncology at City of Hope, will be presenting at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ('SITC'). SITC is being held from November 3-5, 2023, in San Diego, California."

Preclinical • Brain Cancer • Glioma • Oncology • Solid Tumor